Indication intelligence, analysis and sector perception

Neuralstem (CUR) "reorganizes"

May 20, 2016 11:05am

The clock is ticking … as the cash runs out

Neuralstem (CUR) announced a corporate reorganization to focus on advancing its NSI-189 neurogenic small molecule program, currently in a P2 clinical trial for the treatment of major depressive disorder, and to continue to pursue collaborations for the NSI-566 stem cell therapy program.

This reorganization is necessary to efficiently allocate esources on the company's refocused strategy thereby creating value for all stakeholders.

The Bottom Line: CUR’s financial situation is on life support. It is laying off staff and streamlining its activities because money is running out. Cash and short-term investments decreased $4.6 M in Q1/16. While net loss increased nearly 25% or $1.7 M during the same period. CUR’s G&A costs rose 121% in Q1/16 for expenses related to severance accrual and increased stock based compensation resulting from the accelerated vesting of options, both related to the termination of its former CEO.

Meanwhile R&D costs decreased approximately $117 K or 4% during from Q4/15 to Q1/16 due to decreased pre-clinical and clinical costs partially offset by increases in headcount and stock based compensation.

CUR closed flat Thursday at $0.33 and remains flat during Friday’s morning session.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

3 hours 30 min ago
RegMed Investors (RMi) Closing Bell: a tough week; tied to cross-currents of geopolitical conflicts and recurring inflation

15 hours 13 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.